Pharmaron Beijing Co., Ltd. (HKG: 3759)
Hong Kong
· Delayed Price · Currency is HKD
14.10
0.00 (0.00%)
Dec 31, 2024, 12:08 PM HKT
Pharmaron Beijing Revenue
Pharmaron Beijing had revenue of 3.21B CNY in the quarter ending September 30, 2024, with 10.02% growth. This brings the company's revenue in the last twelve months to 11.80B, up 3.25% year-over-year. In the year 2023, Pharmaron Beijing had annual revenue of 11.54B with 12.39% growth.
Revenue (ttm)
11.80B CNY
Revenue Growth
+3.25%
P/S Ratio
n/a
Revenue / Employee
581.18K CNY
Employees
20,295
Market Cap
42.17B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 11.54B | 1.27B | 12.39% |
Jan 1, 2023 | 10.27B | 2.82B | 37.92% |
Dec 31, 2021 | 7.44B | 2.31B | 45.00% |
Dec 31, 2020 | 5.13B | 1.38B | 36.64% |
Dec 31, 2019 | 3.76B | 849.04M | 29.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |